PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
1.94
Very conservative net debt at 50-90% of Biotechnology median of 2.51. Philip Fisher would suggest checking if this conservatism supports R&D and growth investments.
No Data
No Data available this quarter, please select a different quarter.
1.21
Current ratio below 50% of Biotechnology median of 3.96. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.